NAC dynamically reprograms the immune–stromal landscape of PDAC in a regimen- and timing-dependent manner, revealing a transient post-chemotherapy window of immune remodelling.
Abstract
Background Neoadjuvant chemotherapy (NAC) is increasingly incorporated into the management of pancreatic ductal adenocarcinoma (PDAC), yet how treatment regimen and timing reshape the tumour-immune microenvironment remains poorly defined. Methods Targeted immune transcriptomic profiling was performed using NanoString on spatially annotated tumour, stromal, and immune-enriched regions from resected PDAC specimens from 23 patients, including NAC-treated and treatment-naïve cohorts. Key findings were validated and spatially localised using Xenium in situ transcriptomics. Results NAC induced extensive transcriptional remodelling of the tumour microenvironment in a regimen- and time-dependent manner. Tumours resected shortly after FOLFIRINOX exhibited coordinated upregulation and strong spatial coupling of the CXCL12–CXCR4 axis. These correlations were attenuated or reversed at longer post-treatment intervals and following gemcitabine-based therapy. Disrupted stromal coordination of the CCL2–CCR2 axis further highlighted context-dependent effects of chemotherapy on chemokine signalling. Across regions, NT5E (CD73) expression inversely correlated with CD8A, consistent with spatially restricted T cell exclusion. Conclusions NAC dynamically reprograms the immune–stromal landscape of PDAC in a regimen- and timing-dependent manner, revealing a transient post-chemotherapy window of immune remodelling. The clinical significance of this phenomenon requires further investigation to determine whether temporally optimised integration of immunomodulatory and stroma-targeted therapies with NAC can improve patient outcomes. Graphical abstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most treatment-refractory malignancies, with limited and often transient benefit from chemotherapy, targeted therapy, immunotherapy, and radiotherapy. Therapeutic resistance is increasingly recognized as an ecosystem-level process arising from reciprocal intera...
Hong-Jiao Li, Jia-Ning Cui, Xin Yang et al.· Cancer Drug Resistance· 0 citations
Neoadjuvant immune-chemotherapy (nICT) has transformed the treatment strategy for esophageal squamous cell carcinoma (ESCC), yet the molecular mechanisms underlying treatment response remain incompletely understood. To investigate these mechanisms, we jointly analyzed matched ESCC specimens obtained before and after...
Ye-Feng Shen, Yun-Lei Ma, Huan-Song Yang et al.· Cell Death & Disease· 0 citations
Chemotherapy remains the backbone of neoadjuvant treatment for triple-negative breast cancer (TNBC), and response to chemotherapy strongly correlates with patient prognosis. However, predicting chemoresistance remains a major clinical challenge. To address this obstacle, we performed serial fine needle aspirations foll...
Amanda L. Rinkenbaugh, Gloria V. Echeverria, Jian-Su Shao et al.· Oncogene· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies, characterised by rising incidence, poor long-term survival, and profound resistance to systemic therapy. Its poor prognosis reflects late diagnosis, early metastatic spread, and a uniquely desmoplastic, immunosuppressive tumour microe...
A. Lefas, H. Lote, I. Chau· Precision Oncology· 0 citations
These findings position SPP1 + macrophages as central drivers of NAC resistance in CRLM and highlight the spatial immune barrier they create as a promising therapeutic target for overcoming chemoresistance and improving immunotherapy responses.
Jing-Zhi Tang, Wei-Jie Hao, Xi-Gan He et al.· Molecular Biomedicine· 0 citations
It is suggested that productive immunotherapy responses in PDAC require not only tumor-reactive T cells, but also a stromal-vascular niche capable of supporting their recruitment, recirculation and persistence.
Sarah Kang, M. Parikh, Leontios Pappas et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.